In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Abstract Treatment options in multiple myeloma (MM) are increasing with the introduction of
complex multi-novel-agent-based regimens investigated in randomized clinical trials …

We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from
3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive …

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To
estimate the risk of bacterial and viral infections in multiple myeloma patients, we used …

In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple
myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved …

PURPOSE The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study
demonstrated a statistically significant improvement in progression-free survival with …

With growing numbers of elderly multiple myeloma patients, reliable tools to assess their
vulnerability are required. The objective of the analysis herein was to develop and validate …

Recent developments have led to remarkable improvements in the assessment and
treatment of patients with multiple myeloma (MM). New technologies have become available …

This first validation of the International Myeloma Working Group geriatric assessment in 125
newly diagnosed multiple myeloma patients was performed using the International Myeloma …

Lenalidomide-dexamethasone (Rd) is standard treatment for elderly patients with multiple
myeloma (MM). In this randomized phase 3 study, we investigated efficacy and feasibility of …